Myeloma - The Bloodline with LLS

Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.

In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.   

Mentioned on this episode: 

• Minimal/Measurable Residual Disease



• Minimal/Measurable Residual Disease Chart 



• Tests (FISH, Flow Cytometry, Next-generation Sequencing)



• The Revolution of Genomics: How Testing Leads to Individualized Treatment



• Multiple Myeloma



• Acute Lymphoblastic Leukemia

Additional LLS Support Resources: 

• Information Specialists 



• Financial support



• Free telephone/web patient programs 



• Free booklets 



• Clinical Trial Support Center



• Young Adult Resources



• Caregiver support 



• Caregiver Workbook



• Survivorship Workbook



• Online chats 



• LLS Community 



• Support groups 



• Patti Robinson Kaufmann First Connection Program 



• Free Nutrition Consultations

Support for this episode provided by: Adaptive Biotechnologies

The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline with LLS.